Cytosorbents CORP 8-K filings

CytoSorbents Corporation has announced a rights offering to existing shareholders and certain warrantholders, aiming to raise capital and unlock restricted cash.

CytoSorbents announced an 11% increase in product revenue for Q3 2024, alongside key regulatory milestones for DrugSorb-ATR.

CytoSorbents Corporation has authorized an at-the-market equity offering of up to $20 million of its common stock.

CytoSorbents has submitted its DrugSorb-ATR marketing application to the FDA and Health Canada, while also reporting preliminary Q3 2024 financial results including product sales and gross margin estimates.

CytoSorbents Corporation has amended its royalty agreement with ROKK, LLC, clarifying the definition of gross revenue for royalty calculations related to its CytoSorb device and related products.

CytoSorbents Corporation has appointed Peter J. Mariani as its new Chief Financial Officer, effective August 14, 2024, while current CFO Kathleen P. Bloch retires and transitions to a consulting role.

CytoSorbents announced a 10% increase in product sales and a 48% reduction in operating loss for the second quarter of 2024, along with the appointment of a new CFO.

CytoSorbents Corporation has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive trading days.

CytoSorbents Corporation has secured a $20 million credit facility to support its global commercialization efforts and regulatory submissions for DrugSorb-ATR.

CytoSorbents Corporation successfully held its 2024 Annual Meeting, electing five directors, approving executive compensation, a long-term incentive plan amendment, and ratifying its accounting firm.

CytoSorbents Corporation received a notice from Nasdaq for non-compliance with the minimum bid price rule, as its stock price has remained below $1 for 30 consecutive business days.

CytoSorbents announced a robust 14% year-over-year increase in product sales and a significant 8% improvement in gross margins for the first quarter of 2024.

CytoSorbents Corporation's Board of Directors approved amendments to the company's bylaws, updating procedures for stockholder meetings and clarifying legal requirements.

CytoSorbents Corporation's executive team will take temporary salary cuts in exchange for stock options as part of a cost-cutting initiative.

CytoSorbents Corporation announced its fourth quarter and full year 2023 financial results, highlighting a 10% increase in core CytoSorb sales for the year and plans to submit DrugSorb-ATR for regulatory approval.

A randomized controlled trial demonstrates that CytoSorb blood purification significantly improves outcomes in heart transplant patients, reducing organ failure and improving hemodynamic stability.